Exhibit 99.1

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results

– Achieved Positive Clinical Data in Multiple RNAi Therapeutics Programs Including RNAi Proof of Mechanism with ALN-VSP for Liver Cancers, Human Proof of Concept with ALN-TTR for Transthyretin-Mediated Amyloidosis, and Clinical Efficacy with ALN-PCS for Severe Hypercholesterolemia –

– Progressed Additional ‘Alnylam 5x15’ RNAi Therapeutics Programs in Hemophilia, Refractory Anemia, and Hemoglobinopathies –

– Maintained Strong Balance Sheet with $261 Million in Cash, and Expects to End 2012 with Greater than $180 Million in Cash –

CAMBRIDGE, Mass.--(BUSINESS WIRE)--February 9, 2012--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year 2011, and company highlights.

“2011 was a year of remarkable clinical achievement for Alnylam and for RNAi therapeutics. Notably, we reported on positive clinical data in three distinct programs over the past 12 months, including human proof of RNAi mechanism in our ALN-VSP liver cancer program, human proof of concept in our ALN-TTR program for transthyretin-mediated amyloidosis, and clinical efficacy in our ALN-PCS severe hypercholesterolemia program,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “With these important accomplishments in hand, we are now more confident than ever in our ability to harness the RNAi pathway for the development of high impact, innovative medicines as defined in our ‘Alnylam 5x15’ product strategy, focused on genetically defined targets and diseases with high unmet medical need.”

“With clear evidence that RNAi can work in patients, our strategy in 2012 is to focus our near term ‘Alnylam 5x15’ efforts on what we believe to be our highest value opportunities, driving key programs toward pivotal trials,” said Barry Greene, President and Chief Operating Officer of Alnylam. “Indeed, we believe we are positioned to drive a focused execution of key programs toward the market. This includes accelerated clinical development plans for ALN-TTR, which we believe has the potential to become the leading innovative medicine for the treatment of transthyretin-mediated amyloidosis. It also includes ALN-APC, our RNAi therapeutic for the treatment of hemophilia, which represents an exciting opportunity to fundamentally change the management of this genetic disease. We plan to continue to advance additional programs with existing partners and new alliances we intend to form.”


The following information was filed by Alnylam Pharmaceuticals, Inc. (ALNY) on Thursday, February 9, 2012 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Alnylam Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Alnylam Pharmaceuticals, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account